Botensilimab

博特利单抗

Report date: 2026/05/09 20:00:18

Base Information

Drug NameBotensilimab
Drug Alias NameBOT (Agenus)Fc-enhanced CTLA-4 antibodybotensilmabAGEN-1181
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsT lymphocytes stimulants
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsEsophageal adenocarcinomaSolid tumoursMicrosatellite Instability +[25] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumArmeniaCanada +[14] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAgenus Inc
China Registration ClassN/A

Develop Information

Active CompaniesAgenus IncZydus Lifesciences LtdMemorial Sloan Kettering Cancer Center +[5] 
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaSolid tumoursMicrosatellite Instability +[23] 
Inactive IndicationsCarcinoma, Renal CellNeoplasms

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG